Navigation Links
How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
Date:6/15/2012

AMSTERDAM, June 15, 2012 /PRNewswire/ --

Dr Alan Ramsay will present findings of a study in patients with Chronic Lymphocytic Leukemia that will contribute to the design of immunotherapeutic strategies leading to the killing of cancer cells at the 17th Congress of the European Hematology Association in Amsterdam.

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells. T cell activity is tightly regulated by signaling at the contact site (referred to as the "immune synapse") with a target cell. However, the ability of cancer cells to evade T cell recognition and destruction is an emerging hallmark of disease progression. We have previously demonstrated that tumour cells induce impaired T cell immune synapse signaling and killing function in chronic lymphocytic leukaemia patients. The aim of this study was to identify the molecules that mediate this T cell defect in cancer. We designed and performed laboratory assays to identify that the inhibitory molecules CD200, CD270 (HVEM), CD274 (PD-L1), and CD276 (B7-H3) are co-opted by leukaemia cells to induce impaired T cell synapse signalling. We further show that these inhibitory molecules are highly active and mediate impaired T cell function in both haematological malignancies (including follicular lymphoma) and solid carcinoma cells. Of clinical relevance, we demonstrate that the immunomodulatory drug lenalidomide prevented induction of the T cell activation defect by down-regulating tumour cell inhibitory molecule expression and activity. These results establish a novel immune evasion mechanism whereby cancer cells exploit multiple inhibitory signalling pathways to suppress T cell synapse signalling. These pre-clinical findings should help contribute to the design of immunotherapeutic strategies to specifically block these inhibitory molecules in cancer and to repair T cell recognition and killing of cancer cells.

About the EHA Annual Congress

After 16 congresses and constantly increasing number of delegates, the 17th Congress of EHA is taking place in Amsterdam. Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases (in the production) of blood and their treatments. The latest data on research and developments within the wide spectrum of hematology are presented.


'/>"/>
SOURCE European Hematology Association
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New method for producing precursor of neurons, bone and other important tissues from stem cells
2. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
3. Notre Dame researchers develop paint-on solar cells
4. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
5. Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development
6. In solar cells, tweaking the tiniest of parts yields big jump in efficiency
7. Mesenchymal Stem Cells Have New Cell Culture Environment
8. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
9. Scientists Discover How a Bacterial Pathogen Breaks Down Barriers to Enter and Infect Cells
10. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
11. Study dusts sugar coating off little-known regulation in cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... regulatory and technical consulting, provides a free webinar on Performing Quality ... 13, 2016 at 12pm CT at no charge. , Incomplete investigations are still ...
(Date:6/23/2016)... 2016  Amgen (NASDAQ: AMGN ) today ... life sciences incubator to accelerate the development of ... space at QB3@953 was created to help high-potential life ... many early stage organizations - access to laboratory infrastructure. ... launched two "Amgen Golden Ticket" awards, providing each winner ...
(Date:6/22/2016)... 2016 Cell Applications, Inc. and StemoniX ... produce up to one billion human induced pluripotent ... week. These high-quality, consistent stem cells enable researchers ... spend more time doing meaningful, relevant research. This ... manufacturing process that produces affordable, reliable HiPSC for ...
(Date:6/22/2016)... , June 22, 2016  According to Kalorama ... generation sequencing (NGS) market include significant efforts in ... sequencers.  More accessible and affordable sequencers, say the ... demand for consumables including sample prep materials.  The ... for Sample Preparation for Next Generation Sequencing (NGS) ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):